Treatment of bipolar disorder: A focus on medication therapy for mania; Focus on ceftaroline; Agents in late-stage development for the treatment of rare cancers
FDA Sets Action Date for Eylea HD in Retinal Vein Occlusion
If approved, Eylea would be the first treatment for RVO with 8-week dosing. The FDA target action date is Aug. 19, 2025.
Read More
Novo Nordisk Warns about More Counterfeit Ozempic
The FDA has seized several hundred units of counterfeit Ozempic 1 mg
Liver Injury Ends Development of Pfizer’s Oral GLP-1 for Obesity
In one study, once-daily danuglipron resulted in one patient who experienced drug-related elevated liver enzymes.
FDA Approves Biocon’s Avastin Biosimilar
Jobevne is the fifth Avastin biosimilar, which are recombinant humanized monoclonal antibodies used to treat several different types of cancer.
Payers Consider Policy Options for Access to GLP-1 Obesity Medications
A new paper by the Institute for Clinical and Economic Review (ICER) looks at the cost-effectiveness versus affordability issue of obesity medications such as Wegovy and Zepbound.
FDA Announces Goal Date for Resubmitted Bevacizumab to Treat Wet AMD
The FDA has set a goal date of Aug. 27, 2025. If approved, the therapy would be branded as Lytenava and be the first ophthalmic formulation of bevacizumab.